Consistent with its mechanism of action, PF-06873600 treatment led to modest inhibition of CDK PD biomarkers pRb and Ki67 in tumor biopsy tissues that was further enhanced by the combination with fulvestrant, indicating target engagement and modulation. Here, MKI67 is linked to neoplasm.